Researchers have developed a new eye drop–based therapy that could offer a safer and less invasive treatment for retinoblastoma (RB), a rare form of eye cancer that primarily affects children. Treating retinoblastoma is challenging because doctors must first overcome the natural protective barrier surrounding the eye, which prevents many drugs from reaching the tumor.
Although current treatments such as injections, chemotherapy, and radiotherapy can control the disease, they often cause pain, vision loss, and other serious side effects. However, a new approach described in a study published in Science Advances may provide a more effective and patient-friendly alternative.
Using Exosomes to Cross the Eye’s Protective Barrier
The research team focused on exosomes, tiny vesicles naturally released by cells that can transport biological molecules throughout the body. Scientists have increasingly explored exosomes as drug delivery vehicles because they can cross biological barriers while triggering minimal immune reactions.
In particular, the researchers used semen-derived exosomes (SEVs), which naturally contain proteins that help them move through complex biological environments. These proteins allow SEVs to penetrate protective barriers, suggesting they could also help deliver drugs across the ocular barrier.
Engineering Targeted Eye Drops for Tumor Treatment
To test this concept, the researchers created innovative therapeutic eye drops that combine SEVs with folic acid (FA) and a specialized nanozyme system known as CMG. The CMG system contains carbon dots, manganese dioxide, and glucose oxidase, which work together to trigger intense oxidative stress in cancer cells, causing them to self-destruct while leaving healthy tissue largely unaffected.
Meanwhile, folic acid helps target tumor cells, and SEVs encapsulate the therapeutic components while temporarily opening the eye’s protective barriers. The complete system, called FA-SEVs@CMG, enables drugs to reach deeper eye tissues more effectively.
Dual Pathways Enable Efficient Drug Delivery
Interestingly, the engineered eye drops enter the eye through two natural pathways—the corneal route and the conjunctival route. This dual-entry mechanism allows the therapy to deliver drugs from multiple directions, creating what researchers describe as an “omnidirectional attack” against tumors.
As reported by medicalxpress, the SEVs used in the study were isolated from pig semen and loaded with the nanozyme components before being incorporated into the eye drop formulation.
Promising Results in Preclinical Studies
Researchers tested the therapy in cell cultures and animal models, including mice with eye tumors. The results were highly encouraging.
After 30 days of treatment, mice receiving FA-SEVs@CMG eye drops showed a dramatic reduction in tumor size, with only about 2.35% residual tumor mass remaining compared with untreated mice. Additionally, treated mice maintained clear eye structures and normal appearance, whereas untreated animals developed severe blood vessel growth and eye opacity.
Potential Breakthrough in Noninvasive Eye Cancer Treatment
According to the researchers, the SEV-based eye drop platform represents a major advancement in ocular drug delivery. Unlike methods such as microneedles or microparticle injections, this approach avoids structural damage to the eye and reduces the risk of systemic toxicity.
Moreover, the dual-pathway delivery system provides more effective drug distribution compared with traditional methods that rely on single-direction diffusion.
Future Applications and Research Challenges
Despite the promising results, further research is necessary before the therapy can enter human clinical trials. Scientists must address several challenges, including large-scale production of SEVs, maintaining manufacturing consistency, reducing immune reactions, and preventing pathogen contamination.
Nevertheless, the technology could eventually transform treatment for retinoblastoma and other eye diseases, including age-related macular degeneration and diabetic retinopathy. If successful, this noninvasive eye drop therapy could significantly improve outcomes for patients while minimizing treatment-related complications.